– USA, NJ – Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX), today announced the appointment of Dr. Lu Borio, MD, to its Board of Directors.
Dr. Borio brings more than a dozen years of high-level experience advancing major regulatory and policy initiatives on behalf of the U.S. government, notably in her roles at the U.S. Food and Drug Administration.
“We are delighted to welcome Lu to the Eagle Board of Directors. Lu is deeply committed to public health, having served in prominent roles at FDA and the National Security Council. Lu has spent her career at the forefront of U.S. healthcare policy, addressing some of the world’s most complex challenges. Her unique mix of clinical, public health and government experience is highly relevant to our business, and her expertise in infectious diseases and medical product development makes her an ideal addition to the team. We look forward to her valuable insights and perspectives as we continue to work to advance our pipeline of product candidates and maximize our growth potential,” said CEO, Scott Tarriff.
About Dr. Lu Borio
Dr. Lu Borio has served as SVP of In-Q-Tel, an independent strategic investment firm that supports the mission of the United States national security community, since 2019, and served as a member of President Biden’s Transition COVID-19 Advisory Board from November 2020 to January 2021. Previously, Dr. Borio was Director, Medical and Biodefense Preparedness Policy, for the White House National Security Council from 2017 to 2019. In this role, Dr. Borio coordinated the U.S. government’s response and policy regarding national preparedness for, and response to, infectious diseases and biothreats, including Ebola and pandemic influenza.
Previously, Dr. Borio spent nearly ten years at the FDA in roles of increasing responsibility, serving as Acting Chief Scientist from 2015 to 2017, where she delivered strategic leadership and support for the Agency’s regulatory science programs and oversaw a portfolio of projects and initiatives totaling approximately $180 million. Dr. Borio was Assistant Commissioner for Counterterrorism Policy from 2010 to 2017 where she was appointed as the principal architect of the Agency’s Medical Countermeasures Initiative, and Director of the Office of Counterterrorism and Emerging Threats from 2010 to 2015. From 2008 to 2010, Dr. Borio served as Medical Officer where she managed and reviewed a portfolio of vaccines, including those for tuberculosis, malaria, dengue, and other neglected tropical diseases.
Dr. Borio also currently serves as a Senior Fellow for Global Health at the Council on Foreign Relations and on the Scientific Advisory Board of Codagenix, Inc. Dr. Borio earned a Bachelor of Science in Zoology from George Washington University and a Doctor of Medicine from George Washington University School of Medicine.
“Eagle has an attractive mix of established and new areas of investigation, and I believe that my professional background and experiences are well-suited to help Eagle achieve its strategic goals. I am delighted to join the Eagle team and look forward to contributing to the Company’s continued growth and success in addressing unmet medical needs,” said Dr. Luciana Borio.
About Eagle Pharmaceuticals, Inc.
Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing, and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialized products include RYANODEX, BENDEKA, BELRAPZO, and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states.
For more information: https://www.eagleus.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.